Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Irofulven (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Apr 2011 Actual end date (January 2006) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.